

The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia

Julia Castello^{*ΦΣ}, Marisol Cortés^{*Σ}, Lauren Malave^{*}, Andreas Kottmann^{*}, David R Sibley^Ω, Eitan Friedman^{*Φ} and Heike Rebbholz^{*ΔΞΨ}

^{*}Department of Molecular, Cellular & Biomedical Sciences, CUNY School of Medicine, New York, NY USA; ^ΦPh.D. Programs in Biochemistry and Biology, The Graduate Center, CUNY, New York, USA; ^Ω Molecular Neuropharmacology Section, National Institute of Neurologic Disorders and Stroke, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA; ^Δ Institut de Psychiatrie et Neurosciences de Paris (IPNP-INSERM), GHU PARIS psychiatrie et neurosciences, ^ΞDanube Private University (DPU), Krems, Austria

^Ψ **Corresponding Author:** Heike Rebbholz, heikerebbholz@gmail.com

^Σ these authors contributed equally




Fig. S1 Effect of low dose L-DOPA (1mg/kg) and dicyclimine on LID

Mice were rendered dyskinetic with L-DOPA/ Benserazide (3mg/kg/ 10 mg/kg) and on day 34 were tested with low dose L-DOPA (1mg/kg) (A,C,F). Thereafter, L-DOPA (3mg/kg) was injected for 2 more days, after which L-DOPA (1mg/kg) and the M1 muscarinic receptor antagonist dicyclimine (45 mg/kg) were co-injected with L-DOPA and LID was assessed (B,D,E,G). N=7. Graphs show mean values +/- SEM. Statistical analysis was performed using Student's t-test for (A ($p < 0.05$), B ($p = 0.1$)) and 2-way ANOVA (Effect of genotype C: $F(1,72) = 14.1$, $p = 0.0003$, D: $F(1,72) = 10.15$, $p < 0.005$; F: $F(1,72) = 7.46$, $p < 0.01$; G: $F(1,72) = 2.14$). Sidak's multiple comparisons post-test (***, $p < 0.001$; **, $p < 0.01$, *, $p < 0.05$).

A





Fig. S2 Immunohistochemical analysis of pERK in the STN.

Scheme of the localisation of the STN in mouse coronal sections (A). Coronal slices comprising the midbrain region from WT and *Drd5*-KO mice were used for IHC with pERK and ChAT antibodies after chronic L-DOPA/Benserazide (3mg/kg/10mg/kg, i.p.) (B,C). Quantification: For analysis, slices were randomly assigned a hemisphere (D), or higher values of the pairs (left or right sides) were compounded and plotted (E). None of these analyses resulted in a significant difference between hemispheres or genotypes. Graphs show mean values \pm SEM. Statistical analysis was performed using 2-way ANOVA (N=7).






Fig. S3. Immunohistochemical analysis of pERK after acute L-DOPA. Coronal striatal slices from WT and *Drd5*-KO mice acutely treated with L-DOPA/Benserazide (3mg/kg/10mg/kg, i.p.), were used for IHC with pERK and ChAT antibodies (A). Quantification thereof (B, C). Scale bar 100 μ m, arrows point to CINs. Graphs show mean values \pm SEM. Statistical analysis was performed using 2-way ANOVA, ****, $P < 0.0001$ ($N = 6$).




Fig. S4. Immunohistochemical analysis of coronal dorsolateral striatal slices from WT and Drd5-KO mice after chronic L-DOPA/Benserazide (3mg/kg/10mg/kg, i.p.) using pan-pPKA substrate (A) and pHisH3 antibodies (B). Scale bars 100 μ m.